- Home
- PTN
as 05-20-2024 4:00pm EST
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | CRANBURY |
| Market Cap: | 32.9M | IPO Year: | 1993 |
| Target Price: | $17.00 | AVG Volume (30 days): | 580.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.43 - $5.65 | Next Earning Date: | 05-15-2024 |
| Revenue: | $5,902,023 | Revenue Growth: | 52.80% |
| Revenue Growth (this year): | -10.62% | Revenue Growth (next year): | 74.14% |
Share on Social Networks:
Stock Insider Trading Activity of Palatin Technologies Inc. (PTN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DEVEER ROBERT K JR | PTN | Director | Apr 11 '24 | Buy | $2.12 | 6,000 | $12,703.20 | 40,845 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.00 | 1,685 | $3,370.00 | 44,860 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.00 | 7,286 | $14,572.73 | 37,574 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.00 | 200 | $400.00 | 37,574 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.01 | 1,808 | $3,634.08 | 35,566 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.01 | 106 | $213.06 | 35,460 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.02 | 460 | $929.20 | 35,000 | SEC Form 4 |
| DEVEER ROBERT K JR | PTN | Director | Mar 6 '24 | Sell | $2.03 | 155 | $314.65 | 34,845 | SEC Form 4 |
| WILLS STEPHEN T | PTN | Executive VP and CFO/COO | Dec 6 '23 | Sell | $2.42 | 2,807 | $6,778.91 | 329,713 | SEC Form 4 |
| WILLS STEPHEN T | PTN | Executive VP and CFO/COO | Dec 6 '23 | Sell | $2.64 | 2,191 | $5,784.24 | 327,522 | SEC Form 4 |
| DUNTON ALAN W | PTN | Director | Dec 4 '23 | Sell | $2.48 | 199 | $493.52 | 45,075 | SEC Form 4 |
| DUNTON ALAN W | PTN | Director | Dec 4 '23 | Sell | $2.46 | 1 | $2.46 | 45,074 | SEC Form 4 |
Latest Palatin Technologies Inc. News
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
Zacks
5 hours ago
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
GuruFocus.com
5 days ago
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
Thomson Reuters StreetEvents
5 days ago
Q3 2024 Palatin Technologies Inc Earnings Call
PR Newswire
5 days ago
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
PR Newswire
11 days ago
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
PR Newswire
18 days ago
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
PR Newswire
20 days ago
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Insider Monkey
a month ago